Liberty Biosecurity has developed a proprietary biological drug compound that degrades polymicrobial biofilms produced by pathogens in human wounds. Internally designated as Advanced Decontamination and Bio-Neutralization Material (ADBM), this compound is being developed into a portfolio of compound derivatives targeted at multiple types of pathogenic biofilms.
ADBM will be submitted to the U.S. Food and Drug Administration as an Investigative New Drug, with the indication of use as a topical therapy to enhance wound healing in neuropathic diabetic foot ulcers. Globally, this condition afflicts up to 35% of the 422 million people living with diabetes, while in the US alone, diabetic limb complications result in an annual direct cost of $17 billion/year.
ADBM is a novel mixture of hydrolytic enzymes that destroy polymicrobial biofilms by targeting their macromolecular constituents in human wounds: proteins, nucleic acids, lipids and polysaccharides. ADBM is thermostable, effective at elevated temperatures, tolerates a wide pH range, nontoxic, non-conductive, non-corrosive, and does not promote antibiotic resistance. ADBM is produced as a lyophilized powder that can by resuspended in water, glycerol, or delivered under pressure as an aerosolized drug.
A single dose of ADBM removes a significant proportion of polymicrobial biofilms that inhibit wound closure and antibiotic efficacy. In vitro testing has demonstrated ADBM to be efficacious in destroying static and dynamic biofilms produced by gram-negative and gram-positive organisms, including those that contribute to chronic wounds in patients.
ADBM has been subjected to extensive third-party validation. The governments of the United Kingdom and Australia have each independently validated ADBM’s ability to degrade biological targets. Contract research organizations such as Charles River Laboratories and Bode Cellmark Forensics, have conducted efficacy, safety and toxicity testing in support of the drug development program. ADBM’s in vivo drug dose studies were conducted at Northwestern University.
Charles River Laboratories completed tests of ADBM in animals that show no evidence of toxicity.
ADBM’s optimized dose is 1% w/v, although CRO testing has shown that up to 15% w/v can be used in animals without eliciting an immune response.
British and Australian Governments have independently validated ADBM’s ability to degrade biological targets and pathogens of national security importance.
Liberty’s clinical trial program for ADBM is supervised by the following physicians and scientists:
Liberty Biosecurity is a privately-owned life sciences company and a founding member of the EdenRoc Sciences family of companies. Liberty develops solutions to the most challenging problems in biology, national security, and human health. Liberty is headquartered in Virginia with laboratories and offices in Massachusetts, Florida, Thailand and Australia.